Search
Individual-based models of infectious disease dynamics commonly use network structures to represent human interactions. Network structures can vary in complexity, from single-layered with homogeneous mixing to multi-layered with clustering and layer-specific contact weights. Here we assessed policy-relevant consequences of network choice by simulating different network structures within an established individual-based model of SARS-CoV-2 dynamics.
Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine prevents millions of clinical malaria cases in children younger than 5 years in Africa's Sahel region. However, Plasmodium falciparum parasites partially resistant to sulfadoxine-pyrimethamine (with quintuple mutations) potentially threaten the protective effectiveness of SMC. We evaluated the spread of quintuple-mutant parasites and the clinical consequences.
In 2023 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared endemic, yet hospital admissions have persisted and risen within populations at high and moderate risk of developing severe disease, which include those of older age, and those with co-morbidities. Antiviral treatments, currently only available for high-risk individuals, play an important role in preventing severe disease and hospitalisation within this subpopulation.
Immunomodulatory proteins in human milk (HM) can shape infant immune development. However, strategies to modulate their levels are currently unknown. This study investigated whether maternal prebiotic supplementation alters the levels of immunomodulatory proteins in HM.
Since its inception in 2005, the US President's Malaria Initiative (PMI) has played a major role in the reductions in malaria morbidity and mortality observed across Africa. With the status of PMI funding and operations currently uncertain, we aimed to quantify the impact that a fully functioning PMI would have on malaria cases and deaths in Africa during 2025.
This project forms a program of modelling to inform the Gate's Foundation’s malaria product development portfolio, otherwise known as the Integrated Portfolio Management (IPM) project.
At the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meetings in 2024 and 2025, our team convened stakeholder engagement sessions on next-generation malaria vaccines.
This project consists of two linked research programs, working to support malaria control and elimination using OpenMalaria: our in-house, open-source, malaria simulation tool.
Strep A causes a huge global burden of disease, from sore throats to rheumatic heart disease. Our team is developing a computer simulation model, OpenStrepA, to help researchers tackle this disease.
In this project, our team provides malaria vaccine impact predictions to inform vaccine investment strategies for Gavi, the Vaccine Alliance, and their partners.